The researchers who came up with the figures have analyzed more than 50 studies from Europe, Australia and North America and they were published in the journal The Lancet. It was revealed that women who use hormone replacement therapy for a few years are 40% more likely to develop ovarian cancer than the women who never did the HRT.
Current safety guidelines from across the world do not warn about the dangers of HRT when it comes to ovarian cancer. Around six million people in the U.S. and the U.K. use hormone replacement therapy for menopause and gender reassignment.
The Irish Medicines Board stated that the benefits of hormone replacement therapy outweigh the risks when it comes to menopausal women. The Board did warn that the minimum effective dose be used for the shortest period of time.
The study that revealed these findings was carried out by the Collaborative Group on Epidemiological Studies of Ovarian Cancer, organized by the University of Oxford. More than 100 researchers analyzed 52 studies and they found that the risk of developing either of the two most common forms of ovarian cancers (endometrioid or serous) singnificanlty increased in women who had undergone hormone replacement therapy. These women were recent ex-users who at the time of the diagnosis were all within 5 years of last use.
The researchers said that it the cancer risks were similar whether the women used estrogen-progesterone or estrogen-only pills or shots.
The study concluded that the women were still at high risk of developing the two types of ovarian cancers for up to a decade after their last use.
Professor Rob Baber from the University of Sydney and president of the International Menopause Society said that this study simply adds a small increase in risk with use of hormone replacement therapy and that there is no reason for women to stop taking their hormones.
Image Source: Web MD